Mucopolysaccharidosis Type I clinical trials at UCSF
3 in progress, 2 open to eligible people
An Extension Study of JR-171-101 Study in Patients With MPS I
open to all eligible people
Phase I/II, open label, multicenter, multinational (Japan, Brazil and the US) extension study of JR-171-101 for the treatment of MPS I
Oakland, California and other locations
In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases
open to eligible females ages 18-50
The investigators aims to determine the the maternal and fetal safety and feasibility of in utero fetal enzyme replacement therapy in fetuses with Lysosomal Storage Diseases.
San Francisco, California
A Study of JR-171 in Patients With Mucopolysaccharidosis I
Sorry, in progress, not accepting new patients
Phase I/II, open-label, multicenter, multinational (Japan, Brazil and US),designed to evaluate the safety, pharmacokinetics and explore the efficacy for the treatment of mucopolysaccharidosis type I (MPS I).
Oakland, California and other locations
Our lead scientists for Mucopolysaccharidosis Type I research studies include Paul Harmatz Tippi Mackenzie.
Last updated: